JAK inhibitors in rheumatoid arthritis

JAK inhibitors in rheumatoid arthritis

Bibliografische gegevens
Hoofdauteur:	Taylor, PC
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	Springer Nature 2019

Gelijkaardige items

JAK Inhibitors in Rheumatoid Arthritis
door: Kathryn Biddle, et al.
Gepubliceerd in: (2022-08-01)

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
door: Taylor, P
Gepubliceerd in: (2019)

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
door: Taylor, PC, et al.
Gepubliceerd in: (2023)

Pain in rheumatoid arthritis - Could JAK inhibition be the answer?
door: Mehta, P, et al.
Gepubliceerd in: (2020)

JAK inhibitors for the treatment of rheumatoid arthritis
door: Akio Morinobu
Gepubliceerd in: (2020-10-01)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
door: Vishal R. Tandon, et al.
Gepubliceerd in: (2022-07-01)

The Jak/STAT pathway: a focus on pain in rheumatoid arthritis
door: Simon, LS, et al.
Gepubliceerd in: (2020)

JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
door: Rita A. Moura, et al.
Gepubliceerd in: (2021-02-01)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
door: Cutolo M, et al.
Gepubliceerd in: (2013-11-01)

JAK ACADEMY in Rheumatoid Arthritis (RA)
door: Roberto Caporali, et al.
Gepubliceerd in: (2018-09-01)

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
door: Jacopo Angelini, et al.
Gepubliceerd in: (2020-07-01)

Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis
door: Maurizio Benucci, et al.
Gepubliceerd in: (2023-08-01)

New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors
door: Masaru Kato
Gepubliceerd in: (2020-04-01)

Editor’s Pick: JAK Inhibitors in the Treatment Algorithm of Rheumatoid Arthritis: A Review
door: Salvatore Bellinvia, et al.
Gepubliceerd in: (2018-07-01)

Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis
door: Karina Rossi Bonfiglioli, et al.
Gepubliceerd in: (2021-11-01)

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
door: Harrington R, et al.
Gepubliceerd in: (2020-09-01)

The rheumatoid arthritis impact of disease (RAID) score in telemedicine management of rheumatoid arthritis
door: Taylor, PC
Gepubliceerd in: (2024)

Aetiopathology of rheumatoid arthritis
door: Taylor, PC, et al.
Gepubliceerd in: (2022)

Single cell immunoprofile of synovial fluid in rheumatoid arthritis with TNF/JAK inhibitor treatment
door: Xuyang Xia, et al.
Gepubliceerd in: (2025-03-01)

Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis
door: Zhang N, et al.
Gepubliceerd in: (2021-05-01)

Emerging Insights: The Impact of Real-world Evidence on Rheumatoid Arthritis. Latest Evidence from Janus Kinase (JAK) Inhibitors
door: Peter Taylor
Gepubliceerd in: (2024-01-01)

Aetiopathology of rheumatoid arthritis
door: Taylor, PC, et al.
Gepubliceerd in: (2018)

Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry
door: Yoshiya Tanaka, et al.
Gepubliceerd in: (2025-01-01)

Comparative Efficacy and Safety of JAK Inhibitors in the Management of Rheumatoid Arthritis: A Network Meta-Analysis
door: Hani M. Almoallim, et al.
Gepubliceerd in: (2025-01-01)

JAK inhibitors attenuate hyperactivation of nonswitched memory B cells in rheumatoid arthritis patients in remission
door: Jing Luo, et al.
Gepubliceerd in: (2024-07-01)

Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
door: Irma Convertino, et al.
Gepubliceerd in: (2023-03-01)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
door: Soo-Kyung Cho, et al.
Gepubliceerd in: (2023-07-01)

Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study
door: Shuhei Yoshida, et al.
Gepubliceerd in: (2023-10-01)

One of the active ingredients in Paeoniae Radix Alba functions as JAK1 inhibitor in rheumatoid arthritis
door: Lu Xiao, et al.
Gepubliceerd in: (2022-09-01)

Towards better personalised care in rheumatoid arthritis
door: Taylor, PC
Gepubliceerd in: (2025)

Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An extension study
door: Małgorzata Wisłowska
Gepubliceerd in: (2024-11-01)

A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis
door: Rioko Migita, et al.
Gepubliceerd in: (2022-01-01)

Non-Invasive Assessment of Micro- and Macrovascular Function after Initiation of JAK Inhibitors in Patients with Rheumatoid Arthritis
door: Panagiota Anyfanti, et al.
Gepubliceerd in: (2024-04-01)

Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study
door: Małgorzata Wisłowska
Gepubliceerd in: (2022-05-01)

The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile found in the blood of patients with active rheumatoid arthritis
door: Taylor, P, et al.
Gepubliceerd in: (2018)

JAK inhibitors in systemic juvenile idiopathic arthritis
door: Tingyan He, et al.
Gepubliceerd in: (2023-04-01)

The opportunities and challenges of telemedicine in the management of people with rheumatoid arthritis
door: Taylor, PC
Gepubliceerd in: (2022)

Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study
door: Se Rim Choi, et al.
Gepubliceerd in: (2023-07-01)

Treating-to-target or treating the patient in rheumatoid arthritis?
door: Taylor, PC, et al.
Gepubliceerd in: (2019)

Filgotinib, a Janus kinase 1 (JAK1)-selective inhibitor, modulates disease associated cytokines in patients with active rheumatoid arthritis
door: Taylor, P, et al.
Gepubliceerd in: (2019)